Reduced energy intake, resulting from favourable changes in eating behaviour, is the predominant driver of weight loss following bariatric surgery. Here we review the most recent studies examining the impact of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy, the two most common bariatric procedures, upon eating behaviour and the suggested underlying biological mechanisms.
INTRODUCTION
Bariatric surgery is the most effective treatment for people with severe obesity, leading to marked sustained weight loss together with reduced morbidity and mortality. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy are the most commonly performed bariatric procedures undertaken globally [1] . Weight loss induced by lifestyle modification engenders powerful compensatory biological changes leading to increased hunger, enhanced neural responses to food cues and heightened drive to consume energy-dense foods. Together these changes contribute to the high rate of weight recidivism observed following lifestyle intervention weight-management programmes [2 & ]. In contrast, following RYGB or sleeve gastrectomy, despite marked weight loss, hunger is reduced, neural responses to food cues diminish, food becomes less rewarding and a shift in preference away from highfat, high-sugar foods is reported, enabling patients to adopt and maintain favourable changes in eating behaviour [3] . Postoperative changes in gut-derived factors such as gut hormones, nutrients, bile acids, microbiome and neural signals acting peripherally and centrally upon homeostatic and hedonic brain regions are suggested to mediate these postsurgical eating behaviour changes.
Weight-loss following RYGB or sleeve gastrectomy is highly variable with up to 20% of people experiencing poor initial weight loss or weight regain [4] . Emerging evidence suggests a causal link between favourable postoperative eating behaviour
NEW STUDIES EXAMINING THE IMPACT OF BARIATRIC SURGERY UPON SUBJECTIVE AND OBJECTIVE DETERMINANTS OF EATING BEHAVIOUR
Reduced energy intake resulting from decreased consumption of energy-dense food and beverages is suggested to contribute to long-term weight reduction following RYGB [3] and sleeve gastrectomy [8 & ] . The factors determining nutrient selection and subsequent ingestion are complex and include taste, olfaction, subjective pleasure, adverse postingestive gastrointestinal effects and higher executive function.
Most studies examining food preference changes relate to RYGB and have utilized self-report questionnaires. Collectively, these studies suggest that post-RYGB intake of high-fat, high-sugar, unhealthy foods is reduced whilst intake of healthy food items is increased [9 & ]. Recently, however, studies have begun to examine food preference changes post-sleeve gastrectomy. Van Vuuren et al. [10 & ], in a prospective study of 106 individuals undergoing sleeve gastrectomy, reported that most participants experienced a change in the taste, desire and enjoyment of flavours in the first 6 months post-sleeve gastrectomy. Increased intensity of sweet and fatty tastes coupled with decreased enjoyment and desire for these were the most consistent findings. Gero et al. also prospectively assessed the desire to consume different tastes (sweet, sour, bitter, spicy, salt, fatty and umami) in 100 participants pre-sleeve gastrectomy and 6 days and 6 months post-sleeve gastrectomy using food photographs. Preference for all tastes decreased early post-sleeve gastrectomy with greatest decline observed for sweet and fatty foods [11 & ]. However, a 2-year prospective study in 30 sleeve gastrectomy patients suggests these changes in sweet preference may be short-lived; whereas the majority of patients reported changes for sweet and fat tastes at 6 months postsurgery, by 2 years only 23% reported reduced interest in sweet [8 & ] . The accuracy of self-reported food preferences has, however, been questioned. A recent study directly measured food intake during an ad libitum buffet and food preferences using photographs in 31 RYGB and 10 sleeve gastrectomy patients preoperatively and 6 months postoperatively [12 && ]. Energy intake following surgery was halved but the relative intake from high-fat and lowfat, sweet and savoury groups remained unchanged, suggesting that reduced meal size drives reduced energy intake at this time. Interestingly, in the accompanying picture preference test individuals preferentially chose low-fat savoury food postsurgery. The reason for this disparity between selfreported preference and direct measurement is unclear but highlights the need for objective eating behaviour assessments.
Objective changes in food preference post-RYGB have been shown in rodents using nutritive stimuli such as sucrose solution and intralipid. These findings have now been extended to more complex diets. After an 18-day recovery period from sham or RYGB surgery, rats were studied with 8 days free access to four semisolid foods of differing fat and sugar concentrations, alongside standard chow and water [13 && ]. Post-RYGB rats consumed fewer total
KEY POINTS
Reduced preference for high-fat foods is the most common self-reported change in food preference following RYGB or sleeve gastrectomy. This finding is corroborated by objective assessment of food preference changes in RYGB-operated rats with evidence for a learnt response that is inconsistent with the development of conditioned taste aversion.
Sex, type 2 diabetes status, genetics and bariatric procedure type impact upon eating behaviour changes following surgery.
New mechanistic studies implicate PYY, GLP-1, ghrelin, neurotensin and OEA as key gut-derived factors that mediate changes in eating behaviour following RYGB or sleeve gastrectomy.
Brain neuroimaging studies suggest that neuroplastic structural recovery and restoration of functional connectivity as well as changes in neural responses to food cues are normalized following bariatric surgery.
calories than sham-operated rats, whereas a significant decrease in the percentage of calories from sugar-fat whip (high-fat and high-sugar) led to an overall reduction in relative fat intake, increase in nonsugar carbohydrate and a marginal increase in protein. Interestingly these changes were progressive, reaching significance from day 4 onwards, thus suggesting a learned response to the postingestive consequences of different diets. However, RYGB rats, like sham rats, continued to consume the majority of their calories from the high-fat and high-sugar option. Evidently, RYGB rats still found this food item palatable, a finding that is inconsistent with the development of a conditioned taste aversion. Moreover, new evidence from a study in rats without bariatric surgery, in which meal intake exceeding a predefined size threshold was coupled with lithium chloride-induced gastric illness, suggested the existence of a novel phenomenon, 'conditioned meal-size', as opposed to conditioned taste aversion. Here, the adverse consequence of consuming large meals was also learnt [14
&&
]. This phenomenon may be one of the mechanisms by which bariatric surgery leads to reduced meal size and induces weight loss.
Two new cross-sectional studies, one focused predominately on patients in the first postoperative year ] (98 RYGB, 155 sleeve gastrectomy), utilized the same questionnaire to compare the impact of RYGB and sleeve gastrectomy upon selfreported changes in appetite, taste, olfaction and food aversion postoperatively and examined potential association with weight loss. Both studies found the majority of patients following both procedures reported reduced appetite, new food aversions and changes in taste, most commonly for sweet and fat with no differences between RYGB and sleeve gastrectomy groups. These studies differed in their findings relating to self-reported olfactory changes, being more prevalent post-sleeve gastrectomy (52%) compared with post-RYGB (34%) in the early postoperative period [ & ]. Taken together, these new studies suggest that postsurgery change in appetite, taste and smell may contribute to food preference changes following RYGB and sleeve gastrectomy, whilst conditioned meal-size aversion may contribute to reduced meal size. However, large longitudinal studies combining subjective and objective measures of energy intake, food preference, taste and olfaction, with a focus on sex and procedural differences are warranted. Furthermore, in order to evaluate the role of adiposity and weight loss per se in mediating taste and olfactory changes, additional control groups of normal-weight patients, obese weight-stable patients and weight-matched participants who lose weight through dietary restriction also need to be evaluated.
NEW INSIGHTS INTO BIOLOGICAL MECHANISMS UNDERLYING EATING BEHAVIOUR FOLLOWING ROUX-EN-Y GASTRIC BYPASS AND SLEEVE GASTRECTOMY
The biological mediators underlying the marked and sustained weight loss observed following RYGB and sleeve gastrectomy remain incompletely understood. However, there is general agreement that altered nutrient passage and biliary flow either alone or in combination engender changes in a multitude of gut-derived signals. In concert, these modulate brain regions regulating food intake, reward-processing and executive function, ultimately leading to favourable changes in eating behaviour and reduced energy intake.
New evidence supporting a causal role for the anorectic gut hormones glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY) in reducing energy intake post-RYGB has emerged. In individuals post-RYGB, combined GLP-1 receptor antagonism and di-peptidyl-peptidase-4 (DPP-4) inhibition, the enzyme required to generate PYY, led to a 20% increase in energy intake [21 && ]. Isolated GLP-1 receptor antagonism or DPP-4 inhibition had no demonstrable effect, conceivably because of a compensatory rise in the unblocked hormone. Functional neuroimaging studies have shown that altering circulating gut hormone levels or administering gut hormone receptor agonists or antagonists modulates neural response within homeostatic, hedonic and executive function regions in humans [22] . Similarly, brain regions exhibit changes in neural activity post-RYGB coupled with reduced appetitive behaviour for energy-dense foods leading to the suggestion that gut hormones mediate these changes. Evidence in support of this hypothesis comes from a study of RYGB-operated individuals, which coupled a functional magnetic resonance (fMRI) imaging food picture evaluation task with blockage of gut hormone release via administration of a somatostatin analogue. Reduction in circulating PYY levels positively correlated with increase in brain reward system activity, with a similar trend observed for GLP-1 [23
&&
]. Moreover, a prospective, longitudinal fMRI study in RYGB and sleeve gastrectomy candidates with weight-stable controls implicated postoperative suppression of the orexigenic hormone, ghrelin, as a key mediator of changes in liking for highly palatable foods postsurgery. Proposed mechanisms include ghrelin-mediated modulation of dopaminergic neuron activity in the ventral tegmental area (VTA) ( following sleeve gastrectomy, weight loss was associated with altered microbiota and circulating metabolite levels. Additional studies are needed to establish the directionality of this relationship. A reduced preference for and intake of high-fat foods is a consistent finding following RYGB and sleeve gastrectomy. Understanding the postsurgery drivers underlying these changes is, therefore, a key priority. New studies undertaken in RYGB-operated rats by Hankir ]. High-fat intake was reduced in RYGB-operated rats and associated with widespread reduction in MOR availability, particularly in the striatum (Table 1) . Levels of MOR protein were also reduced in the striatum and prefrontal cortex compared with weight-matched rats. The authors concluded that FIGURE 1. Schematic diagram illustrating recent findings in gut-brain signalling pathways proposed to mediate eating behaviour changes after bariatric surgery. Anatomical rearrangement of the gastrointestinal tract leads to reduced circulating levels of ghrelin and increased levels of anorectic gut hormones. Oral intake of the primary bile acid, chenodeoxycholic acid, enhances L-cell release of neurotensin, GLP-1 and PYY even in the absence of luminal nutrients. GLP-1 and PYY act in concert to inhibit energy intake. Neurotensin acts synergistically with GLP-1 and PYY to reduce energy intake and delay gastric emptying. Cross-talk between gut microbiota and bile acids, in addition to new links between microbiota and circulating metabolites involved in energy homeostasis, may play a role. Pathways involving key brain reward centres are proposed to mediate reduced fat preference and intake postsurgery; ghrelin modulates dopaminergic neuron activity in the VTA, OEA acts via vagal afferents to reduce striatal D1R signalling, and reduced MOR signalling in the striatum and prefrontal cortex have been found. Neuroimaging studies suggest that neuroplastic structural recovery, restoration of functional connectivity and normalization of brain responses to food cues also occur. These gut-brain signalling pathways manifest in increased taste and olfactory sensitivity, meal-size aversions and reduced hunger. Whether weight loss per se leads to changed eating behaviour or whether the pathways described occur directly because of surgical intervention, remains unclear. CNS, central nervous system; D1R, dopamine 1 receptor; GLP-1, glucagon-like peptide-1; MOR, m-opioid receptor; OEA, oleoylethanolamide; PPARa, peroxisome proliferator-activated receptor alpha; PYY, peptide YY3-36; VTA, ventral tegmental area.
the reduced fat preference following RYGB may be due to reduced brain MOR signalling.
Brain neuroimaging studies have identified that obesity is not only associated with altered food-cue responses but also structural abnormalities [35, 36] and changes in resting-state connectivity in brain regions involved in energy regulation, reward and motivation [37] . Neuroimaging studies have shown that these obesity-associated neural responses to food cues are 'normalized' following bariatric surgery [ 
EVIDENCE FOR INTERPLAY BETWEEN GENETICS, EATING BEHAVIOUR AND WEIGHT LOSS
Weight loss following RYGB and sleeve gastrectomy is highly variable with genetics estimated to contribute up to 70% of this variability [43] . Candidategene based approaches and hypothesis-free genomewide association studies (GWAS) have been used to identify the genes underlying this variability with limited success, in part due to low sample sizes [44] [45] [46] [47] [48] . Poor postsurgery weight loss can ensue from high-allelic burden of such SNPs [47] . However, even the marked hyperphagia seen in the complex genetic condition Prader-Willi syndrome might be effectively altered by bariatric surgery; Magel2 knockout mice, an animal model of this condition, have shown comparable fat-mass loss and reduced fat intake to wild-type carriers after sleeve gastrectomy [49 && ]. Future large GWAS coupled with detailed eating behaviour phenotyping will hopefully allow informed selection of both surgical candidates and surgical procedures, but may also identify novel pathways that can be targeted nonsurgically to modulate eating behaviour.
CONCLUSION
Changes in taste, olfaction, food preference and food reward following RYGB and sleeve gastrectomy, drive favourable changes in eating behaviour and reduced energy intake. Moreover, obesity-associated neural changes are normalized postoperatively. Changes in gut-derived factors altered as a consequence of anatomical gastrointestinal tract rearrangement acting in concert underlie these changes (Fig. 1) . Emerging data suggest nuanced differences in the impact of RYGB and sleeve gastrectomy upon the determinants of eating behaviour, which most likely reflect their differential impact upon gut-derived hormones. Future longitudinal studies in people undergoing RYGB or sleeve gastrectomy compared with people losing weight through nonsurgical means, with subjective and objective assessments of appetite, taste, olfaction, food preference and food reward together with mechanistic studies are needed to fully elucidate how bariatric surgery alters eating behaviour. A greater understanding of the mechanisms involved and interaction with a person's genetics and presurgery phenotype will allow surgical procedure choice to be tailored to the individual and facilitate discovery of novel nonsurgical treatments for people with obesity.
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